Diet–microbiome synergy underlies obesity-associated immunotherapy efficacy

The interplay between diet, the microbiome, and the effectiveness of immunotherapy in obese individuals has emerged as a critical area of research in oncology. Recent findings suggest that the complex relationship among these elements could explain why some patients with obesity experience better outcomes when undergoing immunotherapy for certain cancers, such as lung cancer and melanoma. This revelation challenges previous assumptions about the role of obesity in cancer treatment and highlights the potential for personalized dietary interventions to enhance therapeutic success. Researchers have long recognized that nutrition plays a significant role in regulating anti-tumour immunity, even before the broader understanding of inflammation's role in cancer development. With the advent of immunotherapies—specifically immune checkpoint inhibitors (ICIs)—there has been growing interest in how lifestyle factors, including diet, can influence both cancer risk and treatment efficacy. Despite the transformative impact of ICIs on treating various cancers, only a fraction of patients achieve lasting remission, underscoring the need to explore individual differences that affect treatment outcomes. The gut microbiota has increasingly become a focal point in this exploration, as it is known to modulate immune responses and potentially influence the effectiveness of ICIs. Obesity is characterized by gut dysbiosis, a disruption in the balance of intestinal microorganisms that is linked to various health risks. However, intriguingly, epidemiological data indicate that individuals with a higher body mass index (BMI) tend to respond better to immunotherapy for certain cancers. This paradoxical observation has prompted researchers to delve deeper into the mechanisms underlying this phenomenon. Traditional preclinical models of obesity, however, have limitations due to their simplified nature, which fails to capture the full spectrum of human dietary diversity and its physiological impacts. To address these gaps, scientists developed a more comprehensive set of dietary models in mice, aiming to replicate the varied eating habits seen in human populations. These models incorporated a wide array of nutrients, including different proteins, carbohydrates, fats, and fibres, to simulate diets such as Mediterranean, Japanese, vegan, American (with and without aspartame), and ketogenic regimens. Additionally, they tested the effects of replacing traditional fibre sources with prebiotics like psyllium, inulin, and pectin, recognizing the potential benefits of these substances in promoting beneficial gut bacteria. After 15 weeks of following these diets, the study revealed a broad spectrum of outcomes, ranging from varying body weights to differences in glucose tolerance, serum insulin levels, and leptin concentrations. These results were compiled into a metabolic score, where higher scores indicated more pronounced metabolic dysfunction. Such detailed profiling allowed researchers to assess how specific dietary components influenced both metabolic health and immune function, providing a nuanced view of how diet interacts with the microbiome to affect overall health and disease susceptibility. The implications of these findings extend beyond basic science, offering new avenues for improving cancer treatment strategies. Understanding the intricate connections between diet, the microbiome, and immune responses could lead to tailored dietary recommendations aimed at optimizing immunotherapy outcomes for patients with obesity. This approach aligns with the principles of personalized medicine, where treatments are customized based on individual characteristics, including genetic makeup, lifestyle, and environmental factors. Future research will likely focus on translating these insights into clinical practice, exploring how specific dietary modifications might enhance the effectiveness of immunotherapy and improve patient prognosis.